CMS commercialised molecules revenue
Q2FY21 : 50 Crores
Q3FY21 : 45 Crores
Q4FY21 : 21 Crores
Q1FY22 : 23 Crores
Q2FY22 : 14 Crores
15 commercialised CMS molecules in Q2FY21 to 18 molecules in Q2FY22.
Number of molecules have increased during this time frame, yet revenue has declined. What might be the reason for this? When a molecule get commercialised, volumes will increase right? Here, revenue of commercialised molecules are decreasing with each quarter.